5 FU infusion with mitomycin‐C vs. 5 FU infusion with methyl‐CCNU in the treatment of advanced upper gastrointestinal cancer. A Southwest oncology group study
5 FU infusion with mitomycin‐C vs. 5 FU infusion with methyl‐CCNU in the treatment of advanced upper gastrointestinal cancer. A Southwest oncology group study
复制标题
5 FU 联合丝裂霉素-C 输注与 5 FU 联合甲基-CCNU 输注治疗晚期上消化道癌症的一项西南肿瘤学小组研究。
作者：
T. Buroker;P. Kim;C. Groppe;J. Mccracken;R. O'bryan;F. Panettiere;J. Costanzi;R. Bottomley;G. W. King;J. Bonnet;T. Thigpen;J. Whitecar;C. Haas;V. Vaitkevicius;B. Hoogstraten;L. Heilbrun
西南肿瘤组（SWOG）在晚期胃癌和胰腺癌中进行了一项随机试验。患者被分配接受每月一次的5-氟尿嘧啶96小时连续输注，其中包括大剂量丝裂霉素C或口服甲基-CCNU。丝裂霉素C和甲基CCNU每8周给药一次。5 FU-丝裂霉素联合治疗播散性胃癌和胰腺癌的缓解率分别为14%和22%。联合输注5 FU和甲基CCNU分别在9%和5%的胃和胰腺肿瘤中实现了缓解。两种肿瘤的肢体间生存率无显著差异。5 FU-丝裂霉素组胃癌的中位生存期为25周，5 FU-甲基-CCNU组为18周。胰腺癌中丝裂霉素组的中位生存期为19周，甲基-CCNU组为17周。白细胞减少症在丝裂霉素组的第一个疗程更严重。回归分析表明，体能状态是预测两种肿瘤生存率的最重要的预处理特征。5 FU联合输注似乎都不能显著改变晚期上消化道肿瘤的不良预后。
A randomized trial was conducted by the Southwest Oncology Group (SWOG) in advanced carcinoma of the stomach and pancreas. Patients were assigned to receive monthly 5‐fluorouracil 96‐hour continuous infusions with either bolus mitomycin‐C or oral methyl‐CCNU. Mitomycin‐C and methyl‐CCNU were administered every eight weeks. The 5 FU‐mitomycin combination produced a 14% and 22% response rate in disseminated stomach and pancreatic carcinoma, respectively. The combination of infusion 5 FU and methyl‐CCNU achieved responses in 9% and 5% of stomach and pancreatic tumors, respectively. There was ho significant difference in survival between limbs for either tumor. Median survival in gastric carcinoma on the 5 FU‐mitomycin regimen was 25 weeks vs. 18 weeks on the 5 FU‐methyl‐CCNU arm. In pancreatic carcinoma median survival on the mitomycin limb was 19 weeks as compared to 17 weeks on the methyl‐CCNU program. Leukopenia was greater for the first course on the mitomycin limb. Regression analysis demonstrated that performance status was the most important pretreatment characteristic for predicting survival in both tumors. Neither 5 FU infusion combination appears to significantly alter the dismal prognosis of advanced upper gastrointestinal neoplasms.